MedTrace Logo

Transplantation of Neural Stem Cell-Derived Neurons for Parkinson's Disease

NCT03309514 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2022-04-12

No results posted yet for this study

Summary

This is a prospective study to demonstrate the safety and efficacy of differentiated neurons-derived from adult CNS progenitors cells transplanted in selected patients with Parkinson's disease.

Conditions

Interventions

BIOLOGICAL

Intracerebral microinjections

Stereotactic delivery of cell suspension into basal ganglia structures

Sponsors & Collaborators

  • NeuroGeneration

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
35 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-30
Primary Completion
2023-12-31
Completion
2024-06-30
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03309514 on ClinicalTrials.gov